Melissa D. et al. demonstrated that GPR109A activation by its endogenous ligand butyrate is a key mechanism for reducing inflammation, as shown by transplanting GPR109A/toxemia cells into a mouse graft-versus-host disease (GVHD) model [32]. Here, HCAR2 is linked to graft versus host disease.